Hence, developing agents that target multiple neurotransmitter systems may provide improved therapeutic benefits.<h4>Methods</h4>This study investigated the effects of acute systemic administration of E100, a dual-active cholinesterase inhibitor (ChEI) and histamine H3 receptor (H3R) antagonist, on scopolamine (SCO)-induced memory impairment in male C57BL/6 mice. Here, HRH3 is linked to memory impairment.